Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Recurrent Extrahepatic Bile Duct Cancer
Liver and Intrahepatic Biliary Tract Cancer
Unresectable Extrahepatic Bile Duct Cancer

Interventions: Drug: selumetinib
Other: laboratory biomarker analysis

Registration Number: NCT00553332

Lead Sponsor: National Cancer Institute (NCI)

Brief Summary: This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Description: PRIMARY OBJECTIVES:

I. To evaluate the objective response rate (complete response \[CR\] and partial response \[PR\]) in patients with unresectable biliary carcinoma treated with AZD6244 (selumetinib).

SECONDARY OBJECTIVES:

I. To evaluate the toxicity profile of this drug in these patients. II. To evaluate the 6- and 12-month survival, 6-month progression-free survival, and overall survival rates of patients treated with this drug.

III. To correlate genetic mutations, epigenetic silencing, and/or protein levels of RAS/RAF/MEK/ERK signaling pathway activation with therapeutic efficacy of AZD6244 in these patients.

IV. To genotype tumors for the presence of RAS mutations (i.e., NRAS, KRAS, HRAS) and BRAF mutations (e.g., V600E) in biliary tumor samples from these patients.

V. To assess the presence of activation of the MEK1, MEK2, ERK, and/or Akt pathways in tumor samples from these patients.

VI. To assess the epigenetic alterations (i.e., methylation) affecting the level of gene/protein expression of RASSF1A, NORE1A, and NORE1B in tumor samples from these patients.

OUTLINE:

Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Formalin fixed paraffin-embedded tissue blocks or fresh tissue samples are obtained from all patients prior to treatment. Tissue samples are analyzed by immunohistochemistry for the expression level of target proteins (MEK, p-MEK, ERK, p-ERK, Akt, p-AKT, RASSF1A, NORE1A and NORE1B); PCR for mutational status of target genes RAS, BRAF and EGFR); and in methylation-specific PCR for methylation of target gene promoters (promoters for RASSF1A, NORE1A and NORE1B). Samples are also analyzed by quantitative real-time PCR to compare methylation status. Fresh frozen tissue, when available, is evaluated by Western analysis to measure expression levels of target proteins.

After completion of study treatment, patients are followed up for 4 weeks.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 29

Inclusion Criteria

Histologically confirmed biliary tract carcinoma
- Surgically unresectable disease
Meets any of the following criteria for biliary cancers only:
- Received ≤ 1 prior systemic anticancer therapy, including chemoembolization
- Received prior cryotherapy, radiofrequency ablation, ethanol injection, transarterial chemoembolization, or photodynamic therapy AND meets the following criteria:
  - More than 6 weeks have elapsed since any of the prior therapy described above
  - Indicator lesion(s) must be outside the area of prior treatment OR must demonstrate clear evidence of disease progression if the only indicator lesion is inside the prior treatment area
  - Indicator lesion must have clearly distinct edges on CT scan
- Prior radiotherapy with or without the use of a fluoropyrimidine as a radiosensitizer is allowed, provided more than 12 weeks have elapsed since treatment
Fresh or paraffin-embedded tissue from tumor blocks must be available for review
Measurable disease, defined as ≥ 1 unidimensionally measurable lesion > 20 mm by conventional techniques or > 10 mm by spiral CT scan
No known brain metastases
Life expectancy > 12 weeks
ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%
ANC ≥ 1,500/μL
Platelet count ≥ 75,000/μL
Total bilirubin ≤ 2 times upper limit of normal(ULN)
AST or ALT ≤ 3 times ULN
Serum albumin ≥ 2.5 mg/dL
INR ≤ 1.5 (not receiving anticoagulation therapy)
Creatinine normal or creatinine clearance ≥ 60 mL/min
Not pregnant or nursing
Negative pregnancy test
Fertile women must use effective contraception during and for four weeks after the last dose of AZD6244
Fertile men must use effective contraception during and for 16 weeks after the last dose of AZD6244
No significant traumatic injury within the past 3 weeks
No uncontrolled symptoms consistent with encephalopathy
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or its excipient, Captisol®
No QTc interval > 500 msecs or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., hypokalemia or family history of long QT interval syndrome), including NYHA class III-IV heart failure
No other malignancy within the past 3 years, except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
No refractory nausea and vomiting, chronic gastrointestinal disease (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption
No uncontrolled concurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situation that would limit compliance with study requirements
No malignant hypertension within the past year
No prior sorafenib or MEK inhibitors
More than 4 weeks since prior chemotherapy, biologic therapy, or immunotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered to ≤ grade 1 adverse events
No major surgery within the past 3 weeks
No other concurrent investigational agents
No concurrent requirement for medication that can prolong the QT interval
No concurrent combination antiretroviral therapy for HIV-positive patients
No concurrent consumption of grapefruit or grapefruit juice

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (enzyme inhibitor therapy)	selumetinib	Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment (enzyme inhibitor therapy)	laboratory biomarker analysis	Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (CR and PR)	Every 8 weeks	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Secondary Outcome Measures

Name	Time	Method
Toxicity Profile of AZD6244	From the time of first treatment with AZD6244, assessed up to 4 weeks	Toxicitity will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 3.0
Median Progression Free Survival for Patients	Up to 6 months	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Overall Survival	Up to 12 months
RAS/RAF/MEK/ERK Signaling Pathway Activation	At baseline
Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation	At baseline	Measure the proteins levels of RAS/RAF/MEK/ERK signaling pathway activation to AZD6244

Trial Locations

Locations (7): University of North Carolina
🇺🇸
Chapel Hill, North Carolina, United States
Vanderbilt University
🇺🇸
Nashville, Tennessee, United States
Ohio State University Medical Center
🇺🇸
Columbus, Ohio, United States
Emory University
🇺🇸
Atlanta, Georgia, United States
University of Michigan Cancer Center (UMCC) Research Base
🇺🇸
Ann Arbor, Michigan, United States
H. Lee Moffitt Cancer Center and Research Institute
🇺🇸
Tampa, Florida, United States
Wayne State University
🇺🇸
Detroit, Michigan, United States